Garenoxacin mesylate hydrate
CAS: 223652-90-2
Ref. 3D-FG40128
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued |
Product Information
- 1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid methanesulfonate hydrate
- 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate (1:1:1)
- 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-, methanesulfonate, hydrate (1:1:1)
- 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-, monomethanesulfonate, monohydrate
- Geninax
Garenoxacin mesylate hydrate is a quinolone antibiotic that suppresses the growth of bacteria by inhibiting DNA-dependent RNA polymerase in prokaryotes. It has been shown to be active against a wide range of bacterial strains. Garenoxacin mesylate hydrate has also been shown to have an antimicrobial effect in patients with infectious diseases or metabolic disorders, such as cervical cancer and autoimmune diseases. This drug binds to the bacterial ribosome and prevents protein synthesis, which leads to cell death. Garenoxacin mesylate hydrate has also been shown to have an antimicrobial effect in patients with infectious diseases or metabolic disorders, such as cervical cancer and autoimmune diseases. This drug binds to the bacterial ribosome and prevents protein synthesis, which leads to cell death.
